Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 with and Without Pembrolizumab in Patients with Treatment-Refractory, Unresectable Melanoma

Next Previous
Search
Trial Profile

A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 with and Without Pembrolizumab in Patients with Treatment-Refractory, Unresectable Melanoma

Status: Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LNS 8801 (Primary) ; Pembrolizumab (Primary) ; Dacarbazine; Ipilimumab; Nivolumab; Relatlimab; Temozolomide
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Linnaeus Therapeutics

    • Most Recent Events

    • 26 Mar 2025 According to Linnaeus Therapeutics media release, company anticipates initiating a randomized controlled clinical trial in unresectable, treatment refractory cutaneous melanoma in Q2 of this year and $2,000,000 Direct-to-Phase 2 Award Funds Study of LNS8801 in the Treatment of Melanoma.
    • 20 Mar 2025 According to Linnaeus Therapeutics media release, company is poised to open enrollment in a randomized, controlled study in the near future
    • 08 Oct 2024 Given protocol has been amended as above-1) Parallel open label assignment has been implemented. Phase has been changed from 3 to 2/3.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top